ProCE Banner Activity

WSG-ADAPT TN: Neoadjuvant Albumin-Bound Paclitaxel + Carboplatin or Gemcitabine in TNBC

Slideset Download
Conference Coverage
In patients with triple-negative breast cancer, 12 weeks of albumin-bound paclitaxel plus carboplatin significantly increased pCR rate vs albumin-bound paclitaxel plus gemcitabine.

Released: December 17, 2015

Expiration: December 15, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation